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A B S T R A C T
Background
Lymphoedema is the accumulation of excess fluid in the body caused by obstruction of the lymphatic drainage mechanisms. Treatment
with Benzo-pyrones is thought to reduce fluid forming in the subcutaneous tissues and reduce pain and discomfort of the affected area.
Objectives
To assess the effectiveness of benzo-pyrones compared to placebo in the management of lymphoedema.
Search strategy
We searched the Cochrane Breast Cancer Group register (September 2003), the Cochrane Central Register of Controlled Trials (The
Cochrane Library, Issue 4,2003), MEDLINE, EMBASE, CINAHL, UnCover, PASCAL, SIGLE, reference lists produced by The
British Lymphology Society, theNational Research Register (NRR) and The International Society of Lymphology congress proceedings.
Selection criteria
Randomised controlled trials comparing Benzo-pyrones with placebo.
Data collection and analysis
Trials were selected for eligibility and tested for quality by two blinded reviewers who independently extracted data. Meta-analysis was
not performed due to the poor quality of the trials.
Main results
Fifteen trials were included. Three oxerutin trials tested the same dose over 6 months against placebo and included a total of 127
participants (data were available for 81). There were insufficient data from these to calculate the per cent reduction or increase in
baseline excess limb volume.
One trial testing Cyclo 3 Fort (approved name) was found (57 participants) but insufficient data was provided to allow a proper analysis
of its findings. A single trial of Daflon (approved name) was found (104 participants) but this also provided insufficient information
to reach a conclusion about the effectiveness of the drug. Three trials of coumarin combined with troxerutin were found which tested
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two different doses of the drug against each other with no placebo, however participant numbers and baseline data were not provided.
Eight trials of coumarin were identified. Two of these reported the same trial and the other potentially also referred to the same trial
but this could not be confirmed. A further two papers also appeared to refer to the same trial but again this was unconfirmed.
Five studies added anti-filarial drugs to the interventions tested. Participant data could not be extracted and the reporting of outcome
measures in most was unclear. Loprinzi’s 1999 trial was reported in more detail but its conclusions were very much at odds with other
findings.
Authors’ conclusions
It is not possible to draw conclusions about the effectiveness of Benzopyrones in the management of lymphoedema from the current
available trials.
P L A I N L A N G U A G E S U M M A R Y
Benzopyrones for reducing and controlling lymphoedema of the limbs
Lymphoedema is an accumulation of excess fluid, mainly in the arms and legs. It can occur in several ways: from birth; as a result of
a parasitic infection; or as a complication of cancer surgery. The most common treatments are compression hosiery (e.g. bandaging,
sleeves, etc.), skin care and exercise. The drugs commonly known as benzo-pyrones have been prescribed to prevent the fluid leakage and
collection which characterises lymphoedema. This review found that there was not enough good quality evidence to draw conclusions
about whether benzo-pyrones are useful either in reducing lymphoedema or the pain and discomfort associated with it.
B A C K G R O U N D
Lymphoedema is a chronic and progressive condition resulting
from an abnormality of, or damage to the lymphatic system. Any
reduction in the capacity of the lymphatic system to drain fluid
from the interstitium (a small gap in the tissue) and return it to the
blood circulation will cause fluid to build up in the skin and the
subcutaneous tissues of the affected part of the body (Mortimer
1995; Levick 1991).
Lymphoedema has many causes but the main ones are:
1.cancer and its treatment - leading to secondary lymphoedema;
2.congenital abnormalities of the lymphatic system - so called
primary lymphoedema;
3.chronic venous disease of the lower limb - lympho-venous
oedema;
4.filariasis, a parasitic infection - leading to secondary lym-
phoedema.
The incidence of lymphoedema following breast cancer treatment
is difficult to assess due to differences in assessments made of diag-
nosis, measurement and follow-up time. Petrek 1998 andErickson
2001 conducted systematic reviews to assess the incidence of breast
cancer related oedema. The included studies assessed its incidence
in Europe, Australia and North America. Using different search
strategies, Petrek 1998 found eight studies which included inci-
dence and Erickson 2001 found ten, including potentially two
studies which were too recent to include in the review by Petrek
1998. Four papers were included in both reviews although one
paper was judged to be retrospective by Petrek 1998 and prospec-
tive by Erickson 2001. Three methods of assessing lymphoedema
were included: volume, limb circumference and self report. The
time scale used for follow-up also varied. Petrek 1998 reported
incidence figures of 6 to 30%, however, the table used to explain
these figures is unclear. Using only axillary dissection papers, in
the review by Erickson 2001 a range of 2.4 to 56%was found. The
range in time of follow-up, where available, seemed to result in the
wide variety of reported findings. The figures for lymphoedema
of the lower limbs were even less reliable yet it appears to be a
major problem. In many other cancers (for example melanoma,
soft tissue sarcoma and pelvic tumours) the treatment often com-
promises lymphatic drainage routes. Chronic venous insufficiency
is also a major contributory factor in the development of chronic
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lower limb oedema, as is filariasis, a parasitic infection endemic
in parts of India and Africa. Moffatt 2003 surveyed healthcare
providers in South West London and found a crude prevalence of
lymphoedema from any cause of 1.33 per 1000. The incidence of
arm oedema was much higher in women, which reflects the large
number of women developing lymphoedema following develop-
ment of breast cancer.
Lymphoedema can result in significant physical and psychological
morbidity. Swelling causes a disproportion in the size of a part of
the body and, as such, can both interfere with mobility and af-
fect sufferers’ perceptions of themselves (Tobin 1993). In addition
to an increase in size of a limb, the affected subcutaneous tissues
gradually thicken and fibrose, forming a solid component to the
swelling (Foldi 1985; Mortimer 1995). The presence of fibrotic
tissue makes it difficult for fluid in the tissues to drain; affected
tissues are often described as “woody”. This explains why estab-
lished lymphoedema does not respond to elevation of a limb and
why it appears to be more resistant to treatment. Often the more
solid limbs are not the biggest in size but, as the fluid is difficult
to mobilise, it seems likely that a cycle of further fibrosis is set up.
The continued presence of fluid in these areas of hardened tissue
provides a stimulus to further thickening. Whether the presence
of fibrosis increases the risk of the acute inflammatory attacks to
which affected patients are prone is not known.
The management of this condition involves decongesting the re-
duced lymphatic pathways as a way of reducing the size of the
affected limb; encouraging the development of collateral drainage
routes; and stimulating the function of remaining patent routes
in order to control the swelling long-term (Foldi 1985; Mortimer
1995). Traditional treatments in Europe have focused on the use
of physical therapies to reduce and control oedema (Foldi 1985).
Complex physical therapy (CPT), using a multi-layer bandaging
technique (Badger 2000) and manual lymph drainage (a specific
form of massage) are used to reduce oedema, followed by a main-
tenance regime of strong compression hosiery, regular exercise and
careful skin care and hygiene.
In most countries of the world, the standard treatment regime
consists of compression hosiery, skin care and exercise. The use of
drugs has also gained favour over the last ten years, particularly
in Australia and Third World countries (Casley-Smith 1993(1);
distance from services and climatic conditions may make the pro-
vision and effectiveness of physical therapy more difficult.
A number of drugs have been used for this condition and mainly
belong to a group known as benzo-pyrones. Formed from a vari-
ety of naturally occurring substances, benzo-pyrones may be plant
extracts, semi-synthetic preparations or wholly synthetic (Ramalet
2000). They can be divided into alpha-benzo-pyrones, which in-
clude the coumarin derivatives; and gamma-benzo-pyrones, which
are the flavonoids (Ramalet 2000). Gamma-benzo-pyrones can be
further subdivided into flavones and flavonols, such as diosmin,
rutin etc.; and flavanes (flavanones) such as hesperidin.
Developed originally for use in vascular medicine, benzo-pyrones
act by reducing vascular permeability (Cesarone 1992; Ramalet
2000; Roztocil 1993) and reduce the amount of fluid forming
in the subcutaneous tissues. Among the most commonly used
benzo-pyrones are:micronized purified flavanoid fraction (MPFF)
known asDaflon, which is a semi-synthetic preparation from dios-
min; oxerutins, such as Paroven and Venorutin; escins (horsechest-
nut) such asVenastat andReparil; coumarins such as 5,6, benzo-al-
pha-pyrone and Lodema; and ruscogenin (butcher’s broom) com-
bined with hesperidin, as in Cyclo 3 Fort. Much higher doses of
these drugs are used in the treatment of lymphoedema than in
venous disease. There is a belief that, as a result of reducing fluid
filtration into the tissues, the drugs have some beneficial effect on
pain and discomfort in the swollen limb. Claims are also made for
the ability of these drugs to increase macrophage activity (Hoult
1996), encouraging the lysis of extracellular protein which in turn
reduces the formation of fibrotic tissue in the lymphoedematous
limb (Piller 1976(1). There have been concerns about the use of
substances such as coumarin long-term, particularly in the doses
used to treat lymphoedema. These doses tend to be higher than
those recommended in venous disease. Australia has withdrawn
coumarin from use because of concerns about liver to
O B J E C T I V E S
1.To assess the effectiveness of benzo-pyrones, compared to
placebo, in reducing limb volume in lymphoedematous limbs
2.To assess the relative effectiveness of different benzo-pyrones in
reducing limb volume in lymphoedematous limbs
3.To assess the impact of benzo-pyrones on the quality of subcu-
taneous tissues in lymphoedematous limbs
4.To assess the effect of benzo-pyrones on pain or discomfort in
lymphoedematous limbs
5.To assess the impact of benzo-pyrones on the lymphoedema
patient’s quality of life
6.To assess the incidence of adverse effects associated with benzo-
pyrones
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Only randomised controlled clinical trials were included in this
review. If crossover designs were used, the data were analysed up
to the point of crossover.
Types of participants
Studies that recruited adults (18 years of age and older) with a
diagnosis of lymphoedema.
Lymphoedema was defined as clinically detectable oedema from a
peripheral cause and of greater duration than 3 months.
For patients with unilateral oedema, the increase in limb volume
of the swollen limb had to be at least 10% above that of the contra-
lateral normal limb volume. This cut-off point is based on infor-
mation regarding the per cent difference in volume between left
and right limbs in the normal population, which can be as high as
8 or 9% (Sitzia 1997). There is no objective means of assessing bi-
lateral lymphoedema and the presence of swelling was determined
by taking a patient history, and by subjectively assessing the feel
and appearance of the affected skin and subcutaneous tissues, in-
cluding the use of Stemmer’s sign, the inability to pick up a fold
of skin at the base of a digit.
Non-cancer and cancer patients could be included; cancer patients
should have completed their cancer treatment at least six months
before entering the trial and be without evidence of recurrent ma-
lignant disease when going into the trial. Participants could have
received prior standard treatment (i.e. have been fitted with a com-
pression garment and followed a regimen of skin care and exercise)
but should not have had a course of Complex Physical Therapy
( i.e. multi-layer bandaging) within the six months leading up to
their inclusion in the trial.
Types of interventions
Any trial that tested one of the following regimes was included for
consideration:
1. Paroven or beta-hydroxyethylrutoside or Venoruton versus
placebo;
2. Coumarin or 5,6 Benzo-alpha-pyrone or Lodema versus
placebo;
3. Venastat or Reparil versus placebo;
4. Cyclo 3 Fort versus placebo;
5. Daflon (MPFF) versus placebo
The above regimens could include standard physical treatment,
as previously defined i.e. compression hosiery , exercise and skin
care, as long as it was given to both groups.
The route of administration could be either oral or intravenous
for the different drugs (for example Cyclo 3 Fort cannot be taken
orally) but the route had to be the same for the one drug. Follow-
up of at least three months was required as it is believed that many
benzo-pyrones, in particular Paroven, may take up to six months
to have any effect. It is possible that other benzo-pyrones may take
less time to take effect and in order not to risk excluding trials of
high quality that may have reported shorter follow-up periods, a
minimum of three months was selected for this review.
Types of outcome measures
The main outcome measure was the measurement of the volumes
of limbs - volume could be measured in litres or millilitres by:
a) water displacement;
b) electronic volometer;
c) or calculated from surface measurements.
Other physical benefits to be noted included:
a) improvement in pain / discomfort scores (using validated meth-
ods of assessment such as visual analogue scales);
b) changes in tonometry assessments of the affected tissues (where
a validated method has been used such as that described by Bates
1994)
c) reduction in the number of attacks of cellulitis;
d) increase in strength and function of a limb if assessed using
validated measures or scales;
e) quality of life;
f ) psychological morbidity;
g) adverse events.
Psychological benefits could be assessed using validated scales such
as:
a) Hospital Anxiety and Depression scale (HAD)
b) Psychosocial Adjustment to Illness Scale (PAIS)
c) A disease specific quality of life scale (e.g. Wesley Clinic Lym-
phoedema Scale Mirolo 1995)
Records of adverse effects relating to the drugs were also to be
kept as both short-term and long-term adverse events were to be
reported.
Search methods for identification of studies
The Cochrane Breast Cancer Group register was searched
(September 2003) using the search strategies of the Cochrane
Breast Cancer group as outlined in the The Cochrane Library. The
Cochrane Central Register of Controlled Trials (The Cochrane
Library, Issue 4, 2003), MEDLINE, EMBASE, CINAHL, Un-
Cover, PASCAL, SIGLE, reference lists produced by The British
Lymphology Society, the National Research Register (NRR) and
The International Society of Lymphology congress proceedings
were searched (from the date of inception of the database until
September 2003).
The reference lists in all the retrieved papers were scanned for
relevant studies. International experts in the field were contacted
to see if they held any unpublished data, as were those found to
be presenting relevant papers in the conference proceedings.
Non-English papers were included.
The terms used for the searches were as follows:
Lymph?edema NOT animal
a) AND benzo?pyrone*;
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b) OR coumarin;
c) OR Lodema
d) OR (5,6 benzo-[alpha]-pyrone);
e) OR beta?hydroxyethylrutoside*;







m) OR Cyclo 3 Fort;
n) OR ruscogenin
Data collection and analysis
One reviewer was designated to scan the titles and abstracts of
the papers identified (CB). Those clearly not relevant, based on a
reading of the abstract, were excluded immediately; if no abstract
was available then a more detailed reading of the paper was made.
If there was any doubt about the eligibility of a paper it was not
excluded at this stage.
Those papers thought to be relevant were then assessed for eli-
gibility according to the set criteria by two reviewers (CB, NP)
working independently. An eligibility form was designed to aid
the selection of papers. All the screening of the papers was carried
out blinded, i.e. with the authors’ names blanked out and with the
papers allocated a number with the letter “D” for the “Drug” used
in front of it, (D1, D2 etc.). A third reviewer (KS) was appointed
to resolve any disagreement over the inclusion of any particular
study.
A data extraction formwas designed and piloted before being used.
Data extraction was duplicated by the second reviewer.
The following data were extracted from the selected studies:
1. details of participants including demographic characteristics,
source of recruitment, site of oedema, cause of oedema, duration
of oedema, relevant co-existing medical conditions;
2. the type and treatment of any cancer including the patient’s
cancer status at the time of the trial (where relevant);
3. the experimental and control interventions including drug,
dosage, route of administration; compliance with allocated treat-
ment; description of the physical treatments used, if any, and con-
firmation that CPT had not been used in the six months before
the trial;
4. long-and short- term adverse events separately for each of the
different drugs (if adverse events were not reported the authors
would were contacted)
5. the homogeniety of the the two treatment groups e.g. in terms
of severity of oedema at the start of the trial;
6. methods of assessment of limb volume and other relevant out-
comes such as tonometry scores, etc;
7. details of any financial support that might introduce a conflict
of interest;
8. the numbers of participants allocated to each group and the
numbers lost to follow-up, or excluded with the reasons why.
Any data from different psychological scales, methods of assessing
the quality of tissues or pain and discomfort etc. were analysed
separately. Adverse events were reported separately for the different
drugs. Results from the trialswere analysed according to the follow-
up time.
Analysis was by intention to treat if the datawere presented as such.
Continuous data, such as the percentage reduction in excess limb
volume or reductionof volume in litres and any scales used to assess
symptoms such as pain, were summarised as standardised means
and standard deviations. These data were plotted to detect the
presence of any skew in reporting. For dichotomous data, such as
the presence or absence of a symptom, the impact of treatment was
expressed as relative risks together with 95% confidence intervals.
Separate comparisons were made for each of the types of inter-
ventions. Meta-analysis was attempted where there were sufficient
trials reporting the same comparison. Standardised mean differ-
ences were combined for the continuous data. Where there was
sufficient homogeneity, the fixed effect model was used to com-
bine the relative risks for the dichotomous data; where significant
heterogeneity was detected, possible explanations were explored
and the random effects model used. Sensitivity analyses were con-
ducted of the effects of cause and site of oedema.
If significant heterogeneity was found then the following were
investigated as possible explanations:
1. type of drug;
2. dosage of drug;
3. duration of therapy;
4. geographical differences;
5. severity of oedema;
6. whether upper or lower limb oedema;
7. cause of oedema;
8. duration of oedema.
Funnel plots were plotted in order to investigate the possibility of
publication bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
From the review of titles 63 papers were considered for full review.
Of these, 15 were included in the review (see table of Character-
istics of included studies), one excluded (Clodius 1978) and 47
were found to be ineligible.
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Review or summary papers
Details of the nine papers reviewing or summarising trials appear
in Additional Table 1. All but two of these, Olszewski 2000 and
Wadworth 1992, involved the same author, (Casley-Smith).
Table 1. Ineligible papers reporting summaries or reviews of trials
Study ID Summary / Review
Olszewski 2000 Summarises 4 trials, only 1 relates to lymphoedema.
Wadworth 1992 Reviews 3 trials relating to lymphoedema, 1 of which is an open-study
Casley-Smith 1999 Claims to review “fifty trials of 4 benzo-pyrones in the treatment of lymphoedema”
Casley-Smith 1992 Summarises 4 trials
Casley-Smith 1993(6) Summarises 3 trials
Casley-Smith 1993(4) Summarises 3 trials
Casley-Smith 1990 Summarises 2 trials
Casley-Smith 1991 Summarises 4 trials
Casley-Smith 1993(5) Summarises 2 trials
In a paper describing the use of micronized purified flavonoid
fraction (MPFF or Daflon 500 mg) in oedema, Olszewski 2000
summarised four trials of the drug. Only one of these studied the
effect of MPFF on lymphoedema; the others investigated its use
in chronic venous insufficiency. Olszewski reported that the lym-
phoedema study (Pecking 1997) was a randomised controlled trial
of 104 women with upper limb oedema following treatment for
breast cancer. Lymphoscintigraphy was used to assess lymph flow
at the start and end of the sixmonth trial. Changes in limb volume,
as measured every two months, was the other outcome. A subset
of 24 patients with severe oedema were analysed separately and
“results showed a significant improvement in the lymphoscinti-
graphic parameters in the MPFF group”. The author omitted to
report that Pecking found no significant differences between ei-
ther the lymphoscintigraphy parameters or the limb volumes of
the MPFF and placebo groups at any point during the trial; the
differences emerged only in the subset with severe oedema. The
only area where a significant difference was detected in all those
who completed the trial was in an analysis of symptoms: a sig-
nificant reduction in the symptom of heaviness was found in the
MPFF group (n= 46) compared to the placebo group (n=48) and
a significant reduction in discomfort in both MPFF (n=45) and
placebo (n= 48) groups. The review failed to discuss adequately the
method of randomisation or blinding and no standard deviations
or confidence intervals were reported. The review also failed to re-
port information about withdrawals (only 94 patients completed
the study) or adverse events, which were reported in six patients
in the placebo group and eight in the MPFF group.
In a review of the pharmacology of hydroxyethylrutosides (HR)
and their therapeutic efficacy in venous insufficiency and related
disorders, Wadworth 1992 included a section on the use of these
drugs in lymphoedema. The authors reviewed two reports of ran-
domised, double-blind, cross-over, placebo-controlled studies (
Piller 1988, Taylor 1993) investigating HR 3g per day over 6
months in a combined total of 48 patients with upper limb lym-
phoedema following treatment for breast cancer and 14 with lower
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limb lymphoedema. In their review of (Piller 1988) they failed to
point out that therewas no information provided about the stage at
which the 10 withdrawals from the study weremade: whether they
were before or after the crossover point. They reported that HR
“reduced limb volume and circumference, increased limb softness
and reduced elevated skin temperatures (all changes significantly
different vs placebo…)”. Treatment also “significantly improved
the sensation of limb swelling, ’bursting’ pain, heaviness, tension
and mobility”. No figures were provided for any of these outcomes
and no mention made of the fact that all the data in the original
paper had to be deduced from graphs. Apparently 97% of patients
“reported increased general well-being” while on HR versus 4%
on placebo and 70% of patients preferred the active treatment. In
their report of the second trial (Taylor 1993) the authors stated
that HR “reduced arm volume by about 10% (p<0.05 vs base-
line)”. Once again this was a crossover trial with no information
about when the withdrawals from the study occurred. A third trial
Braun 1971 reviewed byWadworth and Faulds found an enhanced
effect from the benefits of physiotherapy given to 59 patients after
treatment for breast cancer, whenHR 600mg/day was given to 32
of the patients over four months; but this was an open study, not
a blinded trial. The authors of the review concluded that hydrox-
yethylrutosides had “…improved signs and symptoms of patients
with lymphoedema” and that the recommended dose in such cases
is 3g/day. They stated that while the compound was well tolerated
when used for up to six months, claiming that “most reported
events have been mild and transitory ”, less was known about its
long-term use.
In the remaining seven papers (Casley-Smith 1990, Casley-Smith
1991, Casley-Smith 1992, Casley-Smith 1993(4), Casley-Smith
1993(5), Casley-Smith 1993(6), Casley-Smith 1999), Casley-
Smith reviewed a number of trials of benzopyrones. The largest of
these reviews (Casley-Smith 1999) was said to include 50 clinical
trials. To arrive at this number the trials were categorised accord-
ing to their design and then split according to the grade of lym-
phoedema they studied, treating each of these groups as separate
trials. Thus three of the trials were counted more than once.
Inmany of these review papers there were problems concerning the
interpretation of the numbers of patients involved (nowhere was
the number randomised and the number withdrawn or excluded
reported) and also in the interpretation of the results. There were
inaccuracies, for example in the account of one HR trial (Taylor
1993): the numbers of participants were reported as 44 when that
was the number approached for randomisation and the number
actually randomised was 31; in another (Piller 1988) the number
of patients studied was 80 when the paper gave a figure of 50
patients randomised; in yet another (Mortimer 1995), a figure of
19 patients, when the number actually randomised was 46. In the
MPFF study (Pecking 1997) 104 patients were randomised but
data are only provided for a subset of 24 with severe oedema who
were subjected to a separate analysis; the results on 20 participants
were reported without adding that the authors found no difference
between the active and placebo groups. In addition to inaccuracies
and lack of information, different conclusions were drawn, on
occasion from those of the authors of the papers. In one (Taylor
1993), a 14% reduction in oedema due to the active drug was
reported while the authors themselves reported at most a 10%
reduction and described this reduction as clinically unimportant .
In another (Mortimer 1995), a 30% reduction was reported when
the most that could be deduced from the graphs in this paper
(which were the only source of information) was a reduction of
4%.
In Casley-Smith 1999, after summarising the results of the trials,
a meta-analysis was carried out, including non-randomised and
open trials, followed by a series of sensitivity analyses excluding
those non-double blind trials and non-peer reviewed papers. The
conclusions of the review were that the results were robust and
that benzo-pyrones were responsible for an overall reduction over
one year of 55-71%, depending on the severity of oedema.
Risk of bias in included studies
The 15 studies included in the review are summarised by inter-
vention in Additional tables 02 to 06.
Included studies investigating O-(b-hydroxyethyl)-rutoside
(oxerutin, HR) studies
Three randomised trials testing HR Table 2 were identified. Two
( Mortimer 1995, Taylor 1993) were conducted in England one
(Piller 1988) took place in Australia. Two were of a crossover
design with no washout period (Piller 1988, Taylor 1993); the
third was a parallel group trial (Mortimer 1995). The Australian
paper reported the method of randomisation, saying that separate
randomised lists were used for arm and leg patients, but omitted to
say how allocation was concealed. Information was available from
one set of authors (Mortimer 1995), who confirmed that central
telephone randomisation was used and that blinding was based
on a pharmacy scheme. The other two papers gave no details of
blinding other than to state, in one of them (Piller 1988), that
capsules were supplied by the pharmacy according to randomised
lists. The HR treatment periods were six months in all three trials.
Table 2. O-(b-Hydroxyethyl)-rutoside ( oxerutin, HR) studies
Study ID Methods Participants Interventions Outcomes
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Table 2. O-(b-Hydroxyethyl)-rutoside ( oxerutin, HR) studies (Continued)
Mortimer 1995 6 month parallel group
trial:
Trial groups
1. HR (n 25)
2. Placebo (n 21)
Method of randomisation
not reported but con-
firmed by authors as cen-
tral phone randomisation
used. Blinding based on
a pharmacy scheme us-
ing identical containers &
tabs.













1/12 pain & soreness of
finger nails
1/12 too little oedema
6 month parallel group
trial:
Trial groups
1. HR (n 25)
2. Placebo (n 21)
Method of randomisation
not reported but con-
firmed by authors as cen-
tral phone randomisation
used. Blinding based on
a pharmacy scheme us-
ing identical containers &
tabs.




All female, upper limb
only, all breast ca-related
Nodetails on age, duration
of oedema or cancer treat-
ment
Degree of oedema at start
by group - mean (no SD):
1. 42% Excess Volume
2. 38% Excess Volume
6 months HR 3g daily ver-
sus
6 months placebo daily.
All patients continued
with standard compression
treatment, skin care and
exercises.
Calculated swollen / nor-
mal limb volumes from
surface measurements us-
ing frustrum of a cone for-
mula
6 symptoms assessed on 5
point scale and on Visual
Analogue Scales
Pain assessed on McGill
pain questionnaire
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1/12 pain & soreness of
finger nails
1/12 too little oedema
Taylor 1993 12 month crossover trial
Trial groups:
1. HR first (n 16)
2. Placebo first (n 15)
Method of randomisation
and blinding not reported
Withdrawals 9 in all:
Group 1= 5/16
1/5 possible adverse reac-
tion
1/5 stress of trial
1/5 progression of cancer
2/5 family stress
Group 2= 4/15




1/4 progression of cancer
Not stated whether with-
drawals occurred before or
after crossover
Adverse events see above
44 approached for ran-
domisation, 31 were ran-
domised;
all patients from Lym-
phoedema Clinic;
unilateral upper limbonly;
all but 1 breast ca-related.
1 male 30 female
Degree of oedema at start




Duration of oedema by
groups - mean (SD calcu-
lated from SE):
1. 7.9 yrs (6.0)
2. 7.9 yrs (5.4)
Age by groups - mean (SD
calculated from SE)
1. 56.4 yrs (18.7)
2. 60.3 yrs (10.0)
6 month HR 3 g daily,
6 month placebo.
All patients continued
their usual physical treat-
ment regime of compres-
sion sleeves exercise, mas-
sage & skin care.
Calculated swollen & nor-
mal limb volumes from
surface measurements us-
ing cylinder formula.
Measured tissue tone by
Tonometry. Expressed as
%difference inmmmoved
by weight of tonometer be-
tween swollen & normal
limbs




Pain Quest. and VAS
scores
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Table 2. O-(b-Hydroxyethyl)-rutoside ( oxerutin, HR) studies (Continued)
Piller 1988 12 month crossover trial:
Trial groups - n after with-
drawals:
1. Upper limb HR 1st
(n13)
2. Upper limb placebo 1st
(n13)
3. Lower limbHR1st (n7)
4. Lower limb placebo 1st
(n7)
Upper and lower limbs
randomised according to




10/10 hospital too far
away
Not stated whether with-
drawals occurred before or
after crossover nor which
group they came from
So 40 patients completed
trial
Adverse events: 1/40
1 in placebo grp had nau-
sea & giddiness; not stated




All ISL Grade II oedema:
26/50 with postmastec-
tomy l’oedema of upper
limb
14/50 with l’oedema of
lower limb, due to various
causes
Gender by groups:




Age by groups- mean (SD)
1. 56 yrs (8.6)
2. 59 yrs (10)
3. 51 yrs (15)
4. 49 yrs (22)
Degree of oedema at start
by groups - mean % ex-
cess volume over the nor-






Duration of oedema by
groups - mean (SD)
1. 4.0yrs (5.8)
2. 9.2 yrs (7.0)
3. 16.0 yrs (18.0)
4. 11.0 yrs (12.0)
6 month HR 3g daily, v
6 month placebo - no de-
tails given
All other treat-
ments such as compression
hose stopped 1 month be-
fore trial.
Measured limb volume by
water displacement; (also
circumferences)
Physical symptoms & feel-
ing of well-being scored on
5 point scale from much
worse to improved
Tissue tone measured by
Tonometry at 2 sites on
each limb (proximal & dis-
tal)- the higher the figure
the softer the tissues
Skin temperature mea-
sured by digital skin ther-
mometer - 1 electrode
placed on swollen limb &
1onnormal limb; reported
as % difference between
them
Patients asked their prefer-
ence for treatment
All three studies tested HR against placebo and all three used
a dose of 3g daily. In two of the trials (Mortimer 1995; Taylor
1993), patients continued to follow their usual physical treatment
regimen of compression hosiery, exercises, skin care, and in the
case of one Taylor 1993, self-massage throughout the period of the
trial. In the third trial (Piller 1988), all treatments were stopped
one month before the trial.
Two of the trials (Mortimer 1995; Taylor 1993) looked at the ef-
fect of the drug on unilateral upper limb lymphoedema: all but
one of the patients in these trials had breast cancer-related oedema.
The third trial (Piller 1988), looked at unilateral lower limb lym-
phoedema (primary and secondary to trauma and infection) in
addition to breast cancer related upper limb lymphoedema. No
details of any cancer treatment given to the patients were reported
with the exception of the one male patient with upper limb lym-
phoedema resulting from squamous cell carcinoma of the hand,
in Taylor 1993. Patients with active disease at the start of the trials
were excluded in two of the trials but the third (Mortimer 1995)
included nine such patients. The original plan to stratify for active
disease in the latter trial was dropped due to the small numbers.
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A total of 127 patients were randomised across all three studies.
Only one report (Taylor 1993) stated the number approached for
randomisation (n=44) and the number subsequently randomised
(n=31). Of the total 127 randomised, the investigators either ex-
cluded or withdrew 56 participants leaving a total of 81 patients
included in the analyses. Neither of the crossover trials stated
whether withdrawals and exclusions occurred before or after the
point of crossover, thus allowing the possibility of additional bias
in the results.
Included studies investigating Ruscus aculeatus and hes-
peridin methyl chalcone (Cyclo 3 Fort) studies
We found one randomised trial (Cluzan 1990), testing Cyclo 3
Fort (Table 3), which was conducted in France. Participants were
stratified according to degree of oedema as determined by dif-
ferences in circumference between limbs prior to randomisation.
Mild oedema was defined as a difference in circumference of the
arm (a term usually taken to refer to the upper arm but which was
not used consistently in this sense by the authors) of greater than 2
cms but less than 5 cms; and moderate oedema, of greater than 5
cms but less than 8 cms. The trial had a duration of three months.
Table 3. Ruscus aculeatus & hesperidin methyl chalcone (Cyclo 3 Fort) studies
Study ID Methods Participants Interventions Outcomes
Cluzan 1996 3 month trial in Paris
Subjects stratified accord-
ing to degree of oedema:
mild / moderate; then
randomised to active or
placebo
Method of randomisation
& blinding not reported
Trial groups:
1. Mild Active (n12)
2. Mild Placebo (n12)
3. Moderate Active (n15)
4. Moderate Placebo (n18)
Withdrawals / exclusions
reported according to treat-
ment:
Active groups 4/ 27




1/5 lost to f-up
2/5 lymphangitis
2/5 poor compliance
57 patients from Lymphol-
ogy Unit;
all female;
all with upper limb;
all breast ca-related
oedema.
Degree of oedema at start
not stated
Duration of oedema not
stated
Age not stated except that >
18 yrs
No details of cancer treat-
ment stated
Cyclo 3 Fort (C3F) 3 caps
tds
Versus
Placebo 3 caps tds
plus MLD 2 x week for
those who were already re-
ceiving it. No details on the




using formula for trun-
cated cones. Reported as
% change in excess volume
(ExV)
No baseline data reported
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Table 3. Ruscus aculeatus & hesperidin methyl chalcone (Cyclo 3 Fort) studies (Continued)
Adverse events
By Active / Placebo group:
1. C3F 2/27 GI upset
2. Placebo 2/30 infection
Patients were recruited from a lymphology unit. All were adult
females with unilateral, upper limb oedema following treatment
for breast cancer. No details of the cancer treatment were reported
nor were details of the duration of oedema. They were receiving
manual lymph drainage treatment before the trial and continued
during the trial, on a twice weekly regimen; otherwise no other
treatments were given.
Cyclo 3 Fort (C3F) was tested against placebo (three capsules three
times a day). A total of 57 patients were randomised (the number
approached for randomisation was not stated). Of these, 27 were
randomised to C3F (12 with mild oedema, 15 with moderate)
and 30 were randomised to placebo (12 with mild oedema, 18
with moderate). Nine patients were later excluded or withdrew (4
C3F, 5 placebo). Two patients in the C3F group were withdrawn
at one month and again at two months because of adverse nausea
and abdominal pain. It was not stated at what stage of the trial the
remaining five patients dropped out.
Included studies investigating diosmin plus hesperidin
(Daflon 500mg) study
We found one randomised trial testing MPFF, in the form of mi-
cronised diosmin or Daflon 500mg (Pecking 1997; Table 4). This
trial was conducted in France. Participants were randomised to
one of two groups: active or placebo. The method of randomisa-
tion was not reported nor the method of blinding. The trial lasted
six months.
Table 4. Diosmin + hesperidin (Daflon 500mg) study
Study ID Methods Participants Interventions Outcomes
Pecking 1997 6 month trial in France
Method of randomisation
& blinding not reported
Two treatment groups:
1. Diosmin (n 51)





all with upper limb;
all with breast ca-related
oedema
Degree of oedema at start
not stated
Daflon 500 mg x 2 tabs
daily
versus
placebo x 2 tabs daily
No other treatment given
Calculated excess limb vol-
ume from surface measure-
ments using truncated cone
formula.
Assessed every 2 months
but no data provided for
pts other than for a sub-
set of 24 with “more severe
oedema”:
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Table 4. Diosmin + hesperidin (Daflon 500mg) study (Continued)
10 in all, no reasons given:
1. 5/51
2. 5/53
So 94 completed trial







Onset after cancer treat-




Duration of oedema in




Mean (SD) age by group:
1. 61.5 yrs (10.8)
2. 57.3 yrs (9.8)
Body weight at start by
group - mean (SD):
1. 62.3 kg (8.1)
2. 63.3 kg (8.6)













measure migration speed of
tracer, clearance and half-
life.
No data provided for the 94
only for subset of 24
Assessed discomfort by
VAS.
Heaviness assessed on 4
point scale.
Daflon (500 mg) was tested against placebo and no other treat-
ments were given. Women aged 30 to 80 years old were recruited
to the study, the source of the subjects is unknown. All had mild
to severe unilateral upper limb lymphoedema following treatment
for breast cancer. Details of cancer treatment were given: the ma-
jority of patients were treated with surgery and radiotherapy and
the numbers were balanced between active and placebo groups.
Twice as many patients had received chemotherapy in the placebo
group.
Of the total 104 patients enrolled in the study, 51were randomised
toDaflon and 53 to placebo. There were 10 withdrawals: five from
the active group and five from the placebo group; no information
was given about the reasons for the withdrawals nor when they
occurred.
Included studies investigating coumarin plus troxerutin (Lyse-
dem, coumarin plus TER, CTR) studies
We found three randomised trials investigating the effects of
coumarin and troxerutin (Table 5). Two were conducted in France
(Desprez 1985; Cluzan 1996) and one was a multi-centre trial
from Spain (Burgos 1999). Each trial randomised participants to
one of two trial groups and none of the reports gave details of the
method of randomisation or blinding. The French trials were of 9
months (Cluzan 1996) and 18 months (Desprez 1985) duration
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while the Spanish trial lasted 12 months.
Table 5. Coumarin + troxerutin (Lysedem, coumarin +TER, CTR) studies
Study ID Methods Participants Interventions Outcomes
Cluzan 1990 9 month trial in France
Method of randomisation




Withdrawals / exclusions: 2
in all, no reasons given:
1. 1/?
2. 1/?
Yet states 79 completed
trial






1. 2/2 GI upset
2. 1/1 GI upset
80 patients;
source unknown;
all with secondary upper
limb lymphoedema;
no details on cause of
swelling or on gender.
Degree of oedema at start
not stated




9 months Lysedem 6 tabs
daily,
Group 2:
9 months Placebo 6 tabs
daily
Volume difference between
normal & affected limbs
calculated from circumfer-
ences
No baseline data provided
3 point clinical score as-
sessing hardness, heaviness,
pain, subjective improve-







Desprez 1985 18 month trial in France
Method of randomisation
& blinding not stated
2 trial groups:
1. coumarin for 18 months
n 45
2. placebo for 6 months
then coumarin for remain-
ing 12 months n 46
Withdrawals / exclusions
1 / 92 - ? at what stage




patients all with post-mas-
tectomy lymphoedema
of the upper limb. Presume
all female but not stated.
No differ-
ence between them re age,
affected limb, former treat-
ment, duration of oedema,
circumstances of appear-
ance, infection, subjective
symptoms, ”areas of block-
ing“ according to isotope
lymphography
Group 1
1. Coumarin + trioxyethyl-
rutin 9 tabs for first 6mths;
then 6 tabs up to 18 mths”
Group 2
2. Placebo for first 6 mths
then 6 tabs coumarin TER
up to 18 mths
Assessed circum-
ference measurements at 3
sites: wrist, forearm, arm.
No baseline data given.






logical survey” with isotope
lymphography
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Table 5. Coumarin + troxerutin (Lysedem, coumarin +TER, CTR) studies (Continued)
sea, pollakiuria, pruritus &
menstrual flow. Details not
given of these by group.




At 12 mths by group:
1. n4
2. n0
At 18 mths none.
Burgos 1999 12 month trial in Spain
Trial groups
Grp 1. Lysedem (n 38)
Grp 2. Lysedem (n 39)
Method of randomisation
and blinding not reported
Withdrawals / exclusions:
24 in all:
Grp 1. n 15/38
6/15 voluntary
6/15 adverse events
3/15 lost to f-up
1/15 protocol violation
(Total = 16/38 not 15 as
stated)
Grp 2. n 9/39
1/9 voluntary
5/9 adverse events
1/9 lost to f-up
1/9 “other causes”
(Total = 8/39 not 9 as
stated)
States 53 completed study
“3 more minor protocol vi-
olations” occurred:
Grp 1. n 1
Grp 2. n 2
Adverse events as above
77 patients from 6 centres:
1 breast unit,
2 rehabilitation depts,
2 depts vascular surgery,
1 oncology dept;
all female;
all with unilateral upper
limb;
all breast ca-related lym-
phoedema;
all ISL Grade 2




Duration of oedema not
stated but all less than 10
years
Age by groups - mean (SD)
Grp 1. 52.0 yrs (8.0)
Grp 2. 52.8 yrs (7.0)
Group 1.
coumarin + troxerutin
(Lysedem) 90 mg daily
Group 2
coumarin + troxerutin
(Lysedem) 135 mg daily
Volumes of normal &
affected limbs measured
electronically. Expressed as
changes in excess volume
(ExV)
6 Clinical symptoms as-




sensation of oedema at
wrist, forearm, upper arm.
Patient & investigator as-







- reported as % of patients.
No baseline data
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Each of the trials took a different approach to the interventions
being studied. Cluzan 1996 tested coumarin (Lysedem six tablets
daily) versus placebo; Desprez 1985 tested coumarin plus TER
(nine tablets presumably daily) against placebo for 6 months and
then allowed both groups to take six tablets of the drug for the
remaining 12 months of the trial. No actual doses were given for
either of these studies. The Spanish trial (Burgos 1999) compared
two different doses of Lysedem (90 mg versus 135 mg) over 12
months; there was no placebo group.
All three trials studied patients with unilateral upper limb lym-
phoedema, two (Burgos 1999; Desprez 1985) stated that all pa-
tients had oedema following breast cancer treatment; the remain-
ing trial did not report details concerning gender or cause of
swelling.
A total of 249 patients were randomised and of these, as 27 were
excluded or withdrawn, 222 were included in the analyses. There
were discrepancies in two of the studies (Burgos 1999; Desprez
1985), between the numbers withdrawn and the numbers said
to have completed the study. None of the reports stated when
withdrawals were made.
Included studies investigating 5,6 benzo-a-pyrone (coumarin,
5,6BaP) studies
We found seven reports of randomised trials of 5,6 BaP (Table 6).
Two reports of trials conducted in China, one reported in Chinese
(Zhang 1990), and one in English (Chang 1996), were confirmed
to be the same trial; another (eighth) report, also in Chinese (Gan
1996), might refer to this same trial but no confirmation has been
received from the author and the study is awaiting classification.
Two reports of trials conducted in India (Casley-Smith 1993(1);
Jamal 1989) appear to refer to the same trial although neither
explicitly confirms this link. Another trial was conducted in China
(Casley-Smith 1993(2)), while the remaining two trials took place
in the United States (Loprinzi 1999) and Australia (Casley-Smith
1993(3)). These latter two trials were of a crossover design both
lasting 12 months. The remainder were parallel group trials.
Table 6. 5,6 Benzo-a-pyrone (coumarin, 5,6BaP) Studies
Study ID Methods Participants Interventions Outcomes
Casley-Smith 1993(1) 2 year trial conducted in
India
Subjects matched for
grade, duration, age &
sex in quadruplets then
randomised
Method of randomisa-
tion and blinding not
stated
216 patients bilateral &
unilateral lymphoedema
of the lower limbs sec-
ondary to filariasis
195 attended for initial
assessment
Mean age by group:
1. 50.5 yrs
Groups
1. Placebo + placebo
2. Placebo + BaP
3. DEC + placebo
4. DEC + BaP
BaP 2 x 200mg tabs o.d
DEC 6mg/kg/day
[Was dose calculated in-
Main
outcome was leg volume
assessed 3 mnthly.
Used water displacement
to measure up to 30 cms
above the heel ie only to
level of knee.
Looked at % Ex V over
normal limb. At least
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Table 6. 5,6 Benzo-a-pyrone (coumarin, 5,6BaP) Studies (Continued)
4 trial groups:
1. placebo + placebo n ?
2. placebo + 5,6 BaP n ?
3. DEC + placebo n ?
4. DEC + 5,6 BaP n?
Withdrawals / exclusions




because attended for less
than 2 f-up assessments
n5 / ? ”found BaP tabs
too big to swallow;
n20 /? “did not like their
reactions to DEC”
Presume the 25 above are
part of the 32 excluded
rather than in addition to
them.
States only 163 patients
reported on (giving 183






1. m =9; f=30 total=39
2. m=20; f=32 total=52
3. m=12; f=32 total=44
4. m=20; f=28 total=48
Total = n 183
[At oddswith stated figof
163 patients reported on;
does say there were 183
limbs as some patients
had bilateral swelling]
% Excess volume at start


















dividually for each sub-
ject?
If so did no. of tabs vary?
If so howwas it blinded?]
Placebo - nodetails given
No other treatments
given
20 patients had bilateral
oedema so used means of
normal limbs as control
for bilateral limbs.
Also made circ measure-




Feelings of swelling &
bursting, Also re sec-
ondary infections
Clinical exam of ulcers
Jamal 1989 2 year trial conducted in
India
Subjects put into groups
matched for grade, age,
sex
Method of randomisa-
tion and blinding not
stated
4 trial groups:
Grp 1. placebo + placebo
n 41
169 reported on - ?
whether this was no. ran-
domised.
Only 20 had completed
the trial.
[Mean f-up reported here
is 9.3 months]




1. Placebo + placebo
2. Placebo + BaP
3. DEC + placebo
4. DEC + BaP
BaP 2 x 200mg tabs o.d
DEC 6mg/kg/day
[so was dose calculated
individually for each sub-
ject?
If so did no. of tabs vary?
If so howwas it blinded?]
Main




Looked at % Ex V over
normal limb..
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Table 6. 5,6 Benzo-a-pyrone (coumarin, 5,6BaP) Studies (Continued)
Grp 2. placebo + 5,6 BaP
n 47
Grp 3. DEC + placebo n
39
Grp 4. DEC + 5,6 BaP n
42
Placebo - no details given




Method of blinding not
stated.
2 trial groups:
1. coumarin n 64
2. placebo n 40
Subjects strati-
fied for grade of oedema,
duration, sex and age
Chinese authorities ap-
parently
insisted that more peo-
ple be assigned to treat-
ment than placebo. (but
this was only the case
for Grade 3 oedema -
grades 1 & 2 were similar
size.groups)
Withdrawals / exclusions
21 / 104 in all
8 / 21 withdrew from ac-
tive group in 1st year: 6
/ 8 “reasons unconnected
to drug”; 2 felt they were
cured & refused further
treatment (1 at 1 month,
1 after 5 months).
13/21 withdrew during
2nd year: 11/13 from ac-
tive group; 2/13 from




104 patients with uni-




















Main outcome limb vol-
ume.
States this was calculated
from surface measure-
ments using truncated
cone method BUT else-
where same authors say
that they only looked at
differences in circumfer-
ences;
authors also imply that
whole leg was measured
(they talk about sum-
ming 4 truncated cones)
but the reported volumes
are too small for whole






feature as none, slight,
mild, moderate, severe
18Benzo-pyrones for reducing and controlling lymphoedema of the limbs (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 6. 5,6 Benzo-a-pyrone (coumarin, 5,6BaP) Studies (Continued)
mild”. 60%coumarin pts
felt dizzy / sleepy, 3 slight
nausea & diarrhoea, 2
skin rash. All symp-
toms disappeared after
1st month. 5 patients
withdrew with infective
hepatitis (?? When ?? if
included in withdrawals
above)
Chang 1996 12 month parallel group
trial in China;
Method of randomisa-
tion and blinding not
stated
2 trial groups:
Grp 1. coumarin (n 30)
Grp 2. placebo (n 30)
Stratified for grade of
oedema, age, sex, dura-
tion of oedema, cause of
oedema.
Withdrawals - none re-
ported
60 patients, source un-
known (China) . 23Male




Mean age (SD) by group:
Grp 1. 34.8 (13.6)
Grp 2. 38.6 (15.8)
Mean% Ex Vol by group
(SD calculated from re-
ported SE)
Grp 1. 22.6% (21.90)
Grp 2. 20.1% (19.49)
Group 1
Coumarin 2 x 200mg
daily
Group 2
placebo - no details
After 6 months mi-
crowave heating + ban-
daging given to both
groups daily for 2 courses
of 40 days
Outcomes assessed
monthly but only start &
end reported.
Volume to level of hip
measured by water dis-
placement
Sum of 6 circumferences
taken every 10 cm
Tissue tonometry - ratio
of swollen to normal; in-
crease in values indicates
softening
Symptoms of swelling,
burning pain, feeling of
heaviness, restricted mo-
bility each scored as im-
proved, same, worse
Zhang 1990 same trial as above
Loprinzi 1999 Appears to be Multi-cen-
tre - USA
Method of randomisa-




Grp 1. coumarin 1st (n ?)
Grp 2. placebo 1st (n ?)
Withdrawals /
exclusions:






Stratified for age, cancer
treatment, history of cel-
lulitis,
duration of oedema, time
since surgery / DXT, Ta-
moxifen therapy.
Degree of oedema at start
6 month
coumarin 2x100mg b.d.
/ 2 x lactose tabs b.d then
switched.
Not clear whether or not
women continued with




ing formula for volume
of a cylinder.
Volume Data available
for 120 /140 at 6months;
93 / 140 at 12 months
Also analysed circumfer-
ences 5 set points
Phys-
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Table 6. 5,6 Benzo-a-pyrone (coumarin, 5,6BaP) Studies (Continued)
n 47/140 in all
n 2/47 withdrew at start
(? which groups) - 1 inel-
igible; 1 withdrew start-
ing trt;
n 6/140 stopped treat-
ment by crossover point;
further 12/140 stopped
treatment by end of trial;
n 1/140 died after 6mnth
point;
no vol mea-
surements available for n
26/140 - ? at what point
they did not return
Adverse events:
No diff in either grp ex-
cept for evidence of hep-
atotoxicity: sig. higher
during coumarin -
n 9/139 (6%) v 0 with
placebo
by groups -
Grp 1. 32.9% (SD ?)
ExV
Grp 2. 30.6% (SD ?)
ExV
Baseline grading of phys-
ical symptoms by group:
Grp 1. 1.4 n 67
Grp 2. 1.4 n 71
ical symptoms graded 0-




ness, heaviness, loss of
mobility.
Questioned as
to which medication was
most helpful
Casley-Smith 1993(3) 12 month crossover trial
Randomised by random
number table by pharma-
cist
4 trial groups:
Grp 1. arms coumarin 1st
(n 18)
Grp 2. arms placebo 1st
(n 13)
Grp 3. legs coumarin 1st
(n 10)




n 11 / 63 in all:
n 5 / 31 and n 5 / 21 ei-
ther moved away or had
difficulty reaching study
centre - doesn’t say at
which point they with-
drew;
63 patients source un-
known:
31 with upper limb
oedema all unilateral all
as a result of breast cancer
treatment;
21 unilateral lower limb
of various causes.
All ISL grade 2
Gender by group:
Grp 1. m=0; f=18
Grp 2. m=0; f=13
Grp 3. m=2; f=8
Grp 4. m=3; f=8
Mean age by group (SD
calculated from SE):
Grp 1. 63 (9.75)
Grp 2. 62 (15.12)
Grp 3. 48 (16.10)
Grp 4. 55 (14.89)
Mean duration of
oedema in by group (SD
6 months 2 x 200mgs
coumarin o.d
OR
2 tabs placebo o.d; fol-
lowed by
6 months on the other
treatment.
All other physical treat-
ments stopped I month
before trial.
Main outcome was limb
volume measured by wa-
ter displacement .
Assessments made
monthly but only start &
end reported.
Combined the data so no
baseline for each of the 4
grps
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Table 6. 5,6 Benzo-a-pyrone (coumarin, 5,6BaP) Studies (Continued)
n 1 / 21 excluded as sel-
dom returned for f-up
calculated from SE):
Grp 1. 8.3 (6.78)
Grp 2. 7.5 (6.12)
Grp 3. 15.6 (18.00)
Grp 4. 18.2 (13.90)
The same author, J.R. Casley-Smith, was involved in three of
five of the trials. His assistance in preparing another of the reports
for publication was acknowledged in the paper (Chang 1996), as
was his assistance in reviewing the protocol of the another trial (
Loprinzi 1999). Only two of the reports (Casley-Smith 1993(2);
Casley-Smith 1993(3)) described the method of randomisation,
both used random number tables. In the latter of these patients
were matched prior to randomisation to, amongst other factors,
the severity of their oedema, however, it was reported that the
Chinese authorities insisted that randomisation be weighted in
favour of the treatment group. In practice, this weighting was only
apparent in the smallest group, that of themost severe grade, where
twice as many patients were randomised to treatment; the other
grades were evenly matched in treatment and placebo groups.
One report (Chang 1996) stated that “double-blind procedures”
were followed but did not specify what these were. The remaining
studiesmade nomentionof themethodof blinding.The reports of
the Indian trial (Casley-Smith 1993(1); Jamal 1989) raise doubts as
to how the trial was blinded. In this trial therewere four trial groups
and two drugs, BaP and diethylcarbamazine (DEC), compared in
combination and with placebo. The dose of DEC was calculated
as 6mg/kg per day but no further detail was given. Among the
list of reasons for withdrawals, the investigators stated that some
“found the BaP tablets too big to swallow” and that some “did
not like their reactions to DEC”, suggesting that it was possible
to distinguish treatments.
All of the trials tested the same dose of coumarin (400mg once
a day) against placebo. One of the Chinese trials (Chang 1996)
addedmicrowave heatingplus bandaging to the treatment regimen
for both groups for the second half of the 12 month trial. The
Indian trial (Casley-Smith 1993(1); Jamal 1989) and the second
Chinese trial (Casley-Smith 1993(2)) were apparently conducted
concurrently and tested BaP against placebo, BaP against DEC,
DEC against placebo, and placebo against placebo. A total of 583
patients appear to have been randomised and of these, 132 were
withdrawn or excluded.
In all reports, it was difficult to trace the numbers withdrawn and
the numbers included in the analyses; the reasons for withdrawal
were seldom given in detail. The report of the American trial (
Loprinzi 1999) and Chinese trial (Casley-Smith 1993(2)) were
clearer about withdrawals than any of the others but even here
there were discrepancies. In the first of these, a crossover trial, two
participants were reported as withdrawing at the start of the trial
but it was not clear from which group; the number reported as
starting the trial on placebo first (n=71) was reported differently
(n= 70) in the first figure outlining the results.
The second crossover trial took place in Australia (Casley-Smith
1993(3)) and gave reasons for the exclusions but did not clar-
ify whether they took place before or after the crossover point.
The Chinese trial investigating heat plus coumarin (Chang 1996,
Zhang 1990) had no withdrawals. The report of the Indian trial
(Casley-Smith 1993(1)), which allowed the inclusion of patients
with bilateral oedema, introduced confusion by referring to the
number of affected limbs (n=183) as well as the number of partici-
pants (n=163 out of 216). A table giving details of the gender, age,
grade and duration of the oedema of the patients in all four trial
groups (n=183) is at odds with the number of patients (n=195)
who attended for initial assessment. Nowhere were the figures for
the number of patients (as opposed to limbs) reported.
Effects of interventions
Included studies investigating O-(b-hydroxyethyl)-rutoside
(oxerutin, HR) studies
All three trials used changes in limb volume as the main outcome
of treatment : two trials (Mortimer 1995; Taylor 1993), calculated
limb volumes from surface measurements while the third (Piller
1988), used water displacement. One trial measured skin temper-
ature (Piller 1988) and twomeasured tissue tone with a tonometer
(Piller 1988; Taylor 1993). All three trials assessed physical symp-
toms.
There was insufficient data provided in any of the trials to calculate
the per cent reduction, or increase, in baseline excess limb volume.
Standard deviations or confidence intervals and the numbers in
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the groups at the different stages of the trial were missing for all the
data in two of the reports (Mortimer 1995; Piller 1988) and for
much of the data in the third, making any attempt at meta-analy-
sis impossible. The authors of one of the English trials (Mortimer
1995) concluded that there had been some slight benefit from the
active drug on limb volume, in effect the oedema had been sta-
bilised while the use of placebo resulted in a small increase; but
no effect on symptoms. These findings were echoed in the sec-
ond English trial (Taylor 1993). The investigators concluded that
while on HR, volume and tissue tone had been reduced by clin-
ically unimportant amounts, with no effect on symptoms. They
did not recommend its use in established lymphoedema. The au-
thors of the Australian trial (Piller 1988) reported that the active
drug “showed significant to very significant improvements” com-
pared to placebo, in volume, skin temperature, tissue tone and
symptoms.
Included studies investigating Ruscus aculeatus and hes-
peridin methyl chalcone (Cyclo 3 Fort) studies
The main outcome in this single trial of C3F (Cluzan 1990) was
limb volume as calculated from surface measurements using the
formula for a truncated cone. Physical symptoms were assessed us-
ing visual analogue scores: mobility, feelings of softness and heavi-
ness. “Arm quality” was assessed by both patients and investigators
and reported as “improved”, “no change” or “deteriorated”.
No baseline data on the per cent excess limb volume was provided
and the results were reported as reduction or increase of the per
cent excess volume (presumably mean results). Mild and moder-
ate lymphoedema were also reported separately; as were arm and
forearmmeasurements. The numbers in the groups at each follow-
up point were not given nor the standard deviations or confidence
intervals. The active groups were reported as expressing a total de-
crease in the whole limb of 1% at one month; 9% at two months;
and 13% at three months. In the placebo groups, the total decrease
was 0.5% at one month; an increase of 1% at two months; and
an increase of 3% at three months. The VAS scores for symptoms
were not reported and no baseline data reported. Data were ex-
pressed as a per cent increase or decrease in the symptoms. By the
end of the trial, softness, heaviness and mobility were all increased
in the C3F group (up by 112%, 33%, 34% respectively) while
softness and mobility were reduced in the placebo group (by 5%
and 2% respectively) and heaviness increased (5%). It is difficult,
logically, to explain the large apparent increase in heaviness in the
C3F group. In the assessment of arm quality, it seems that the fig-
ure quoted was the per cent of patients and investigators reporting
that category. In the C3F group, 70% of patients reported im-
provement as against 32% in the placebo group. Presumably the
figure for investigators relates to the per cent of patients showing
improvement: 75% in the C3F group and 20% in the placebo
group.
The authors concluded that C3F caused a significant reduction
in arm oedema, compared to placebo, and that the reduction was
more marked in the forearm than the upper arm. They suggested
this is due to a greater ratio of fat to fluid in this part of the limb.
Included studies investigating diosmin plus hesperidin
(Daflon 500mg) study
In the only study of Daflon (Pecking 1997), the main outcomes
were lymphoscintigraphic parameters (lymphatic migration speed
as an indirect measure of lymphatic pumping, clearance and half-
life measured as the diffusion of the technetium-labelled colloid)
assessed at the start and end of the trial; limb volumewas calculated
from circumference measurements using the formula for a trun-
cated cone. Visual analogue scales were used to assess discomfort;
heaviness was scored on a four point scale from “absent”, “incon-
stant ”(presumably meaning intermittent), “constant” , “invalid”
(probably a mistranslation of “incapacitating”). Assessments were
carried out every two months.
Ninety-four patients completed the study, 46 on active drug and
48 on placebo. The authors concluded that there were no signif-
icant differences between the active and placebo groups in any of
the lymphoscintigraphic parameters or for volume over time; no
actual data were provided. Both groups were reported as showing
significant reductions in discomfort and, unlike the findings in
the C3F study (Piller 1988), the active group showed a significant
improvement in heaviness. A greater proportion of patients with
constant heaviness fell into the intermittent category and the fig-
ures for the incapacitating category did not change at all . Data on
the results of lymphoscintigraphy and volume were provided for
a “subset ” of 24 patients considered to have more severe oedema
( 10 on Daflon, 14 on placebo); severe oedema was defined as
an arm circumference measurement of greater than 2 cm over the
normal arm. In the C3F study (Cluzan 1990) reviewed above a
circumference of greater than 2 cm and less than 5cm over the
normal arm was considered an indicator of mild oedema so it is
difficult to see how the above criteria defined severe oedema. In this
subset, Daflon significantly improved migration speed and half-
life; clearance was not significantly different between the groups
but showed a greater tendency to improve in the Daflon group.
Changes in discomfort, heaviness and volume were not signifi-
cantly different between the two groups. The excess volume had
increased by 13% in the placebo group (n=14) and decreased by
6% in the Daflon group (n= 10). No values for SDs were given
Included studies investigating coumarin plus troxerutin (Lyse-
dem, coumarin plus TER, CTR) studies
Two of the three studies (Burgos 1999; Desprez 1985) used limb
volume as the main outcome measure, the third uses limb circum-
ferences at three set points on the limb. In addition, lymphoscinti-
graphic parameters (speed, clearance and half-life) was used in
one of the studies (Desprez 1985), and a “morphological survey”
was conducted using isotope lymphography in another (Cluzan
1996). All three included subjective assessments of symptoms; one
(Cluzan 1996) also reported on episodes of infection, and one (
Burgos 1999) asked patients and investigators to assess efficacy.
There were problems with the reporting of the results of trials
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in all three papers. None reported the numbers in the groups at
each assessment nor supplied standard deviations or confidence
intervals. Baseline data was usually missing, making interpreting
any changes difficult.
Included studies investigating 5,6 benzo-a-pyrone (coumarin,
5,6BaP)
The main outcome measure in all identified trials was change in
the size of the affected limb. The American trial (Loprinzi 1999)
calculated limb volume from circumference measurements using
the formula for volume of a cylinder. TheAustralian (Casley-Smith
1993(3)) and one of the Chinese trials (Chang 1996) used water
displacement to measure the whole of the limb volume.
A problem arose with the measurements used in the second Chi-
nese trial (Casley-Smith 1993(2)), which reported using the trun-
cated cone method to calculate volume from circumferences.
However it was clear that only half the lower limb was measured
as the volumes reported were too small for them to represent the
whole limb. The authors did not make this point explicit but did
state that oedema predominantly affected the lower leg and foot.
This was in contrast to the Indian study where the whole leg was
affected. Even if this difference were so, omitting to measure the
whole limb leaves open the possibility that while part of the limb
reduced, another part did not, a tendency revealed in the French
trial of C3F (Cluzan 1990).
In the Indian trial, the authors make clear in the second report (
Casley-Smith 1993(1)) that water displacement was used to mea-
sure limb volumes only up to 30 cm from the heel (i.e. to the
level of the knee); this was despite the statement that the whole leg
tended to be affected. In addition, they included the patients with
bilateral oedema (estimated at 20) in the data analyses by using
the mean of the normal limbs in the trial as controls rather than
each patient being their own control.
For those trials not reporting change as the percentage reduction
or increase in the excess volume over the normal limb, it was
possible to calculate this figure from the data provided in only one
trial (Loprinzi 1999). The authors’ conclusions were based on an
analysis that ignored the crossover design (as did the authors of
the Australian crossover trial (Casley-Smith 1993(3)). Data were
available, however, on normal and swollen limb volumes, which
allowed results to be calculated for the original trial groups. This
was important in the case of crossover trials with withdrawals
after the crossover point, since any data after this point could be
considered biased. Standard deviations were reported or could be
calculated for only two of the trials (Casley-Smith 1993(3); Chang
1996).
The three trials involving the same author, (Casley-Smith 1993(1);
Casley-Smith 1993(2); Casley-Smith 1993(3); Jamal 1989) and
the Chinese trial looking at heat plus BaP (Chang 1996; Zhang
1990), all concluded that BaP was significantly more effective at
reducing oedema than placebo and more effective at improving
physical symptoms. In the case of the Indian study (Casley-Smith
1993(1); Jamal 1989) and one of the Chinese trials (Casley-Smith
1993(2)), these reductions were apparently very large. The Amer-
ican trial (Loprinzi 1999) concluded that there was no difference
observed between BaP and placebo in any of the outcomes under
investigation. There was insufficient data across the included trials
to draw any conclusions on secondary outcomes such as quality
of life, pain and tonometry.
D I S C U S S I O N
For many patients with chronic oedema, particularly those living
in tropical countries or in places where services are inaccessible,
the idea of a drug to treat their condition is very appealing. The
history of using benzo-pyrones to treat lymphoedema dates back
many years and was perhaps an inevitable progression from their
use in venous disease. The main focus of these drugs is to limit
fluid filtration rather than stimulate drainage; there are also claims
for their ability to lyse proliferative tissue. Unfortunately, the trials
described here do little to strengthen the argument for using these
substances to treat lymphoedema. This is an oedema that results
not for the most part from increased filtration of fluid but from a
reduced capacity to drain fluid. Although some studies recruited
adequate numbers of patients, it was difficult to be confident of the
quality of these trials because of the lack of information provided.
For the most part it proved difficult to keep a tally of the patients
recruited, randomised and withdrawn, making the findings diffi-
cult to interpret. The quality of the reporting of these trials was
certainly too low to allow any attempt at meta-analysis.
This review has highlighted the need for consensus on the use of
objective outcomes to assess the effects of treatment on chronic
oedema. Limb volume (of the whole limb rather than just the
affected part so as to pick up any tendency simply to shift fluid
from one part to another) is really the only way to monitor ex-
cess volume; circumferences, even if taken at frequent intervals,
provide limited information. There is a need, where possible, to
use the normal contra-lateral limb as a control since factors such
as weight gain or loss and environmental factors, such as ambient
temperature, can affect the size of the limbs. Oedema extending
onto the body is a relatively common occurrence in lymphoedema
and is difficult to assess. A sensitive objective method of doing so
is needed. Lymphoscintigraphy is gaining recognition as an ex-
cellent tool in the diagnosis of lymphoedema and the differential
diagnosis of the various types of lymphoedema. It has not yet been
proven to be effective and consistent in measuring lymph flow and
is, therefore, of limited value in assessing changes as a result of
treatment.
There is a growing recognition that researchers must look beyond
the immediate and most obvious problem of size when studying
lymphoedema and take into account other outcomes such as the
quality of the affected soft tissues. This presents a challenge to
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provide non-invasive assessment. When it comes to assessing out-
comes such as pain or discomfort and other quality of life issues,
there is scope for modifying existing tools and validating that they
measure problems specific to lymphoedema.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is not possible to draw conclusions about the effectiveness of
Benzopyrones on lymphoedema from these trials. On an individ-
ual basis, patients may report an improvement in symptoms such
as heaviness, tightness or aching when taking these preparations
but any improvement should be weighed against the lack of in-
formation about the long-term effects of these drugs. It is difficult
to see how their routine use could be supported by the current
evidence.
Implications for research
As with so many aspects of the management of lymphoedema,
good quality, properly randomised, multi-centre (preferably inter-
national) trials are required to answer questions surrounding the
use of benzo-pyrones in the management of this condition.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Burgos 1999
Methods 12 month trial in Spain
Trial groups
1. Lysedem (n 38)
2. Lysedem (n 39)
Method of randomisation and blinding not reported










1/9 lost to f-up
1/9 “other causes”
(=8/39 not 9)
States 53 completed study
“3 more minor protocol violations” occurred:
1. 1
2. 2
Adverse events as above
Participants 77 patients from 6 centres: 1 breast unit,
2 rehabilitation depts,
2 depts vascular surgery,
1 oncology dept;
all female;
all with unilateral upper limb;
all breast ca-related lymphoedema;
all ISL Grade 2
Degree of oedema at start by group
1. 25.9%
2. 22.6%
Duration of oedema not stated but all less than 10 years
Age by groups - mean (SD)
1. 52.0 yrs (8..0)
2. 52.8 yrs (7.0)
Interventions Group 1.
coumarin + troxerutin (Lysedem) 90 mg daily
versus
Group 2
coumarin + troxerutin (Lysedem) 135 mg daily
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Burgos 1999 (Continued)
Outcomes Volumes of normal & affected limbs measured electronically. Expressed as changes in excess volume (ExV)
6 Clinical symptoms assessed by investigator on 5 point scale: hardness, heaviness, neurological signs, sensation of
oedema at wrist, forearm, upper arm.
Patient & investigator assessed efficacy of treatment as none, mild, moderate, good, excellent - reported as % of
patients. No baseline data
Notes
Casley-Smith 1993(1)
Methods 2 year trial conducted in India
Subjects matched for grade, duration, age & sex in quadruplets then randomised.
Method of randomisation and blinding not stated
4 trial groups:
1. placebo + placebo n ?
2. placebo + 5,6 BaP n ?
3. DEC + placebo n ?
4. DEC + 5,6 BaP n?
Withdrawals / exclusions
21 / 216 did not appear for initial assessment;
32 / 216
excluded because attended for less than 2 f-up assessments;
5 / ? ”found BaP tabs too big to swallow;
20 /? “did not like their reactions to DEC”
Presume the 25 above are part of the 32 excluded rather than in addition to them.
States only 163 patients reported on (giving 183 limbs as some were bilateral)
Participants 216 patients bilateral & unilateral lymphoedema of the lower limbs secondary to filariasis
195 attended for initial assessment






1. m =9; f=30 total=39
2. m=20; f=32 total=52
3. m=12; f=32 total=44
4. m=20; f=28 total=48
Total = 183
[At odds with stated fig of 163 patients reported on; does say there were 183 limbs as some pts were had bilat swelling]
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1. Placebo + placebo
2. Placebo + BaP
3. DEC + placebo
4. DEC + BaP
BaP 2 x 200mg tabs o.d
DEC 6mg/kg/day [so was dose calculated individually for each subject? If so did no. of tabs vary? If so how was it
blinded?]
Placebo - no details given
No other treatments given
Outcomes Main outcome was leg volume assessed 3 monthly. Used water displacement to measure up to 30 cm above the heel
ie only to level of knee. Looked at % Ex V over normal limb. At least 20 patients had bilateral oedema so used means
of normal limbs as control for bilateral limbs.
Also made circ measurements but did not report on these
Patients questioned about symptoms:
Feelings of swelling & bursting, Also re secondary infections
Clinical exam of ulcers
Notes
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Casley-Smith 1993(2)
Methods 2 year trial conducted in China
Randomised using random number tables.
Method of blinding not stated.
2 trial groups:
1. coumarin n 64
2. placebo n 40
Subjects stratified for grade of oedema, duration, sex and age.
Chinese authorities apparently insisted that more people be assigned to treatment than placebo. (but this was only
the case for Grade 3 oedema - grades 1 & 2 were similar size groups)
Withdrawals / exclusions
21 / 104 in all
8 / 21 withdrew from active group in 1st year: 6 / 8 “reasons unconnected to drug”; 2 felt they were cured & refused
further treatment (1 at 1 month, 1 after 5 months).
13/21 withdrew during 2nd year: 11/13 from active group 2/13 from placebo group. “all for reasons unconnected
to trial”
Adverse effects “weremild” 60% coumarin pts felt dizzy/sleepy, 3 slight nausea& diarrhoea, 2 skin rash. All symptoms
disappeared after 1st month. 5 patients withdrew with infective hepatitis (?? When ?? if included in withdrawals
above)















No other treatments given
Outcomes Main outcome limb volume. States this calculated from surface measurements using truncated cone method [but
elsewhere same authors say that they only looked at differences in circumferences; authors also imply that whole leg
was measured (they talk about summing 4 truncated cones) but the reported volumes are too small for whole leg
must be below knee only.]
Assessed condition of skin, hair growth,ulcers, freq of infection. Categorised each clinical feature as none, slight,
mild, moderate, severe
Notes
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Casley-Smith 1993(3)
Methods 12 month crossover trial
Randomised by random number table by pharmacist
4 trial groups:
1. arms coumarin 1st (n 18)
2. arms placebo 1st (n=13)
3. legs coumarin 1st (n=10)
4. legs placebo 1st (n=11)
Withdrawals / exclusions:
11/63 in all
5/31 and 5/21 either moved away or had difficulty reaching study centre - doesn’t say at which point they withdrew
1/21 excluded as seldom returned for follow up
Participants 63 patients source unknown:
31 with upper limb oedema all unilateral all as a result of breast cancer treatment
21 unilateral lower limb of various causes.
















Interventions 6 months 2 x 200mgs coumarin o.d
OR
2 tabs placebo o.d;
followed by
6 months the other trt.
All other physical trts stopped 1 month before trial.
Outcomes Main outcome was limb volume measured by water displacement
Assessments made monthly but only start & end reported
Combined the data so no baseline for each of the 4 grps
Notes
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Chang 1996
Methods 12 month parallel group trial in China;
Method of randomisation and blinding not stated
2 trial groups:
1. coumarin (n 30)
2. placebo (n 30)
Stratified for grade of oedema, age, sex, duration of oedema, cause of oedema.
Withdrawals - none reported
Participants 60 patients, source unknown (China) . 23 Male & 37 female with unilateral lower limb lymphoedema of various
causes
Mean age (SD) by group:
1. 34.8 (13.6)
2. 38.6 (15.8)




Coumarin 2 x 200mg daily
Group 2
placebo - no details
After 6 months microwave heating + bandaging given to both groups daily for 2 courses of 40 days
Outcomes Outcomes assessed monthly but only start & end reported.
Volume to level of hip measured by water displacement
Sum of 6 circumferences taken every 10 cm
Tissue tonometry - ratio of swollen to normal; increase in values indicates softening
Symptoms of swelling, burning pain, feeling of heaviness, restricted mobility each scored as improved, same, worse
Notes
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Cluzan 1990
Methods 3 month trial in Paris
Subjects stratified according to degree of oedema : mild / moderate; then randomised to active or placebo
Method of randomisation & blinding not reported
Trial groups:
1. Mild Active (n12)
2. Mild Placebo (n12)
3. Moderate Active (n15)
4. Moderate Placebo (n18)
Withdrawals / exclusions reported according to treatment:
Active groups 4/ 27








By Active / Placebo group:
1. C3F 2/27 GI upset
2. Placebo 2/30 infection
Participants 57 patients from Lymphology Unit;
all female;
all with upper limb;
all breast ca-related oedema.
Degree of oedema at start not stated
Duration of oedema not stated
Age not stated except that > 18 yrs
No details of cancer treatment stated
Interventions Cyclo 3 Fort (C3F) 3 caps tds
Versus
Placebo 3 caps tds
plus MLD 2 x week for those who were already receiving it. No details on the n in each group receiving MLD
Outcomes Calculated limb volume from surface measurements using formula for truncated cones. Reported as % change in
excess volume (ExV)
No baseline data reported
Notes
33Benzo-pyrones for reducing and controlling lymphoedema of the limbs (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cluzan 1996
Methods 9 month trial in France




Withdrawals/exclusions: 2 in all, no reasons given
1. 1/?
2. 1/?
Yet states 79 completed trial;





1. 2/2 GI upset
2. 1/1 GI upset
Participants 80 patients;
source unknown;
all with secondary upper limb lymphoedema;
no details on cause of swelling or on gender.
Degree of oedema at start not stated
Duration of oedema not stated
Age not stated
Interventions Group 1:
9 months Lysedem 6 tabs daily,
Group 2:
9 months Placebo 6 tabs daily.
Outcomes Volume difference between normal & affected limbs calculated from circumferences
No baseline data provided
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Desprez 1985
Methods 18 month trial in France
Method of randomisation & blinding not stated
2 trial groups:
1. coumarin for 18 months n=45
2. placebo for 6 months then coumarin for remaining 12 months n=46
Withdrawals / exclusions
1 / 92 - ? at what stage which group, or why
Adverse effects
Included dizziness, nausea, pollakiuria, pruritus & menstrual flow. Details not given of these by group.
At 6 mths by group:
1. 6
2. 2
At 12 mths by group:
1. 4
2. 0
At 18 mths none.
Participants 92 patients all with post-mastectomy lymphoedema
of the upper limb. Presume all female but not stated.
Nodifference between them re age, affected limb, former treatment, duration of oedema, circumstances of appearance,
infection, subjective symptoms, ”areas of blocking“ according to isotope lymphography
Interventions Group 1
1. Coumarin + trioxyethylrutin 9 tabs for first 6 mths; then 6 tabs up to 18 mths”
Group 2
2. Placebo for first 6 mths then 6 tabs coumarin TER up to 18 mnths
Outcomes Assessed circumference measurements at 3 sites: wrist, forearm, arm
No baseline data given
Reported % change in circ at each site
Also assessed subjective symptoms
Episodes of lymphangitis
“Morphological survey” with isotope lymphography
Notes
Jamal 1989
Methods 2 year trial conducted in India
Subjects put into groups matched for grade age sex
Method of randomisation and blinding not stated
4 trial groups:
1. placebo + placebo n=41
2. placebo + 5,6 BaP n=7
3. DEC + placebo n=9
4. DEC + 5,6 BaP n42
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Jamal 1989 (Continued)
Participants 169 reported on - ? whether this was no. randomised.
Only 20 had completed the trial
[Mean f-up reported here is 9.3 months]
Pts chosen with “apparently normal” contra-lateral leg
Interventions Groups
1. Placebo + placebo
2. Placebo + BaP
3. DEC + placebo
4. DEC + BaP
BaP 2 x 200mg tabs o.d
DEC 6mg/kg/day
[so was dose calculated individually for each subject?
If so did no. of tabs vary?
If so how was it blinded?]
Placebo - no details given
Outcomes Main outcome was leg volume assessed 3 mnthly.
Used water displacement to measure. Looked at % Ex V over normal limb..
Notes
Loprinzi 1999
Methods Appears to be Multi-centre - USA
Method of randomisation and blinding not stated
12 month crossover trial:
Trial groups:
1. coumarin 1st (n ?)
2. placebo 1st (n ?)
Withdrawals / exclusions:
47/140 in all
2/47 withdrew at start (? which grps) - 1 ineligible; I withdrew starting trt
6/140 stopped treatment by crossover point;
further 12/40 stopped treatment by end of trial
1/140 died after 6mnth point;
no vol measurements available for 26/140 - ? at what point they did not return
Adverse events:
No diff in either grp except for evidence of hepatotoxicity : sig. higher during coumarin - n 9/139 (6%) v 0 with
placebo
Participants 140 patients aged 33-84; unknown source;
with breast cancer-related l’oedema of upper limb
All were women;
Stratified for age, cancer treatment, history of cellulitis, duration of oedema, time since surgery / DXT, Tamoxifen
therapy.
Degree of oedema at start by groups -
1. 32.9% (SD ?) ExV
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Loprinzi 1999 (Continued)
2. 30.6% (SD ?) ExV
Baseline grading of physical symptoms by group:
1. 1.4 n=67
2. 1.4 n=71
Interventions 6 month coumarin 2x100mg b.d. / 2 x lactose tabs b.d then switched.
Not clear whether or not women continued with their usual physical treatment.
Outcomes Calculated volume from surface measurements using formula for volume of a cylinder.
Volume Data available for 120 /140 at 6 months; 93 / 140 at 12 months
Also analysed circumferences 5 set points
Physical symptoms graded 0-3: none to severe, assessed by questionnaire:
Swelling, pressure, tightness, heaviness, loss of mobility
Questioned as to which medication was most helpful
Notes
Mortimer 1995
Methods 6 month parallel group trial:
Trial groups
1. HR (n 25)
2. Placebo (n 21)
Method of randomisation not reported but confirmed by authors as central phone randomisation used. Blinding
based on a pharmacy scheme using identical containers & tabs.





1/15 persistent upset stomach





1/12 pain & soreness of finger nails
1/12 too little oedema
Participants 46 patients randomised from Lymphoedema Clinic
All female, upper limb only, all breast ca-related
No details on age, duration of oedema or cancer treatment
Degree of oedema at start by group - mean (no SD):
1. 42% Excess Volume
2. 38% Excess Volume
Interventions 6 months HR 3g daily versus
6 months placebo daily.
All patients continued with standard compression treatment, skin care and exercises.
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Mortimer 1995 (Continued)
Outcomes Calculated swollen / normal limb volumes from surface measurements using frustrum of a cone formula
6 symptoms assessed on 5 point scale and on Visual Analogue Scales
Pain assessed on McGill pain questionnaire
Notes
Pecking 1997
Methods 6 month trial in France




Withdrawals/exclusions: 10 in all, no reasons given:
1. 5/51
2. 5/53
So 94 completed trial










all with upper limb
all with breast ca-related oedema.
Degree of oedema at start not stated
Onset after cancer treatment by group - mean months (SD)
1. 33.8 (48)
2. 35.1 (39.4)
Duration of oedema in months at start by group, mean (SD):
1. 46.8 (59.9)
2. 31.1 (39.4)
Mean (SD) age by group:
1. 61.5 yrs (10.8)
2. 57.3 yrs (9.8)
Body weight at start by group - mean (SD):
1. 62.3 kg (8.1)
2. 63.3 kg (8.6)
Surgery (% of pts) by group:
1. 98%
2. 100%
Radiotherapy (% of ots) by group:
1. 82.4%
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Pecking 1997 (Continued)
2. 90.6%
Chemotherapy (% of pts) by group:
1. 33.3%
2. 60.4%
Interventions Daflon 500 mg x 2 tabs daily
versus
placebo x 2 tabs daily
No other treatment given
Outcomes Calculated excess limb volume from surface measurements using truncated cone formula.
Assessed every 2 months but no data provided for pts other than for a subset of 24 with “more severe oedema”:
Used lymphscintigraphy to measure migration speed of tracer, clearance and half-life.
No data provided for the 94 only for subset of 24
Assessed discomfort by VAS.
Heaviness assessed on 4 point scale.
Notes
Piller 1988
Methods 12 month crossover trial:
Trial groups - n after withdrawals:
1. Upper limb HR 1st (n13)
2. Upper limb placebo 1st (n13)
3. Lower limb HR 1st (n7)
4. Lower limb placebo 1st (n7)
Upper and lower limbs randomised according to separate lists. No details on blinding.
Withdrawals / exclusions: 10 in all
10/10 hospital too far away;
Not stated whether withdrawals occurred before or after crossover nor which group they came from .
So 40 patients completed trial
Adverse events: 1/40
1 in placebo grp had nausea & giddiness; not stated whether upper or lower limb
Participants 50 patients randomised source unknown.
All ISL Grade II oedema:
26/50 with postmastectomy l’oedema of upper limb
14/50 with l’oedema of lower limb, due to various causes
Gender by groups:




Age by groups- mean (SD)
1. 56 yrs (8.6)
2. 59 yrs (10)
3. 51 yrs (15)
4. 49 yrs (22)
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Piller 1988 (Continued)





Duration of oedema by groups - mean (SD)
1. 4.0yrs (5.8)
2. 9.2 yrs (7.0)
3. 16.0 yrs (18.0)
4. 11.0 yrs (12.0)
Interventions 6 month HR 3g daily, v
6 month placebo - no details given
All other treatments such as compression hose stopped 1 month before trial.
Outcomes Measured limb volume by water displacement; (also circumferences)
Physical symptoms & feeling of well-being scored on 5 point scale from much worse to improved
Tissue tone measured by Tonometry at 2 sites on each limb (proximal & distal)- the higher the figure the softer the
tissues.
Skin temperature measured by digital skin thermometer - 1 electrode placed on swollen limb & 1 on normal limb;
reported as % difference between them
Patients asked their preference for treatment
Notes
Taylor 1993
Methods 12 month crossover trial
Trial groups:
1. HR first (n 16)
2. Placebo first (n 15)
Method of randomisation and blinding not reported
Withdrawals 9 in all:
Group 1= 5/16
1/5 possible adverse reaction
1/5 stress of trial
1/5 progression of cancer
2/5 family stress
Group 2= 4/15
1/4 possible adverse reaction
1/4 family stress
1/4 viral hepatitis
1/4 progression of cancer
Not stated whether withdrawals occurred before or after crossover
Adverse events see above
Participants 44 approached for randomisation, 31 were randomised;
all patients from Lymphoedema Clinic;
unilateral upper limb only;
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Taylor 1993 (Continued)
all but 1 breast ca-related.
1 male 30 female
Degree of oedema at start by groups - mean % ExV (no SD reported):
1. 35%
2. 30%
Duration of oedema by groups - mean (SD calculated from SE):
1. 7.9 yrs (6.0)
2. 7.9 yrs (5.4)
Age by groups - mean (SD calculated from SE)
1. 56.4 yrs (18.7)
2. 60.3 yrs (10.0)
Interventions 6 month HR 3 g daily,
6 month placebo.
All patients continued their usual physical treatment regime of compression sleeves exercise, massage & skin care.
Outcomes Calculated swollen & normal limb volumes from surface measurements using cylinder formula.
Measured tissue tone by Tonometry. Expressed as% difference inmmmoved by weight of tonometer between swollen
& normal limbs
Assessed joint mobility by scoring functional movements
Assessed pain using McGill Pain Quest. and VAS scores
Notes
Zhang 1990
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Characteristics of excluded studies [ordered by study ID]
Clodius 1978 States that 92 out of 133 patients were “randomised” to treatment while 41 patients received nothing - but it is not
clear that they were really randomised. The treated patients were seen in one department of the hospital while the
untreated patients were seen in other departments and knew nothing of the trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 25 September 2003.
22 October 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 2, 2004
16 August 2003 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
CB was the principal reviewer and wrote up the review. CB and NP were responsible for the extraction of the data. NP acted as the
second reviewer and collated the final draft of the review. PM provided clinical direction and both KS and PM advised, and helped
write both the protocol and the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Royal College of Nursing, UK.
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External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticoagulants [therapeutic use]; Benzopyrans [∗therapeutic use]; Coumarins [therapeutic use]; Diosmin [therapeutic use]; Extrem-
ities; Hydroxyethylrutoside [analogs & derivatives; therapeutic use]; Lymphedema [∗drug therapy]; Plant Extracts [therapeutic use];
Randomized Controlled Trials as Topic
MeSH check words
Humans
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